Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target of $22.00.

Soumit Roy has given his Buy rating due to a combination of factors surrounding aTyr Pharma’s recent developments. The interim results from the Phase 2 EFZO-CONNECT trial for efzofitimod in SSc-ILD patients showed promising outcomes, with 75% of the evaluated patients experiencing significant improvements in skin thickness, a key indicator of disease activity. Additionally, the treatment was well-tolerated, with no adverse events reported, which underscores its potential safety profile.
While the company has not disclosed specific dosage information or comparisons to the placebo group, the anticipation of further data, particularly regarding lung function, adds to the potential upside. Investors are also keenly awaiting the Phase 3 trial results in pulmonary sarcoidosis expected in the third quarter of 2025, which could further validate efzofitimod’s efficacy and safety. These factors contribute to the positive outlook on aTyr Pharma’s stock, justifying the Buy rating.

In another report released on May 21, Leerink Partners also reiterated a Buy rating on the stock with a $16.00 price target.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATYR in relation to earlier this year.